Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07551583
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUGGiven by IV
- Doxorubicin Hydrochloride — DRUGGiven by IV
- Vinblastine — DRUGGiven by IV
- Dacarbazine — DRUGGiven by IV
Study Details
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
Key Dates
- Start date
- Oct 1, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2032
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase II: Treatment with Nivolumab + AVDTreatment will be administered on an inpatient and outpatient basis. Participants will be admitted for day 1 of chemotherapy for cycle 1 and evaluated for 1 or more days following chemotherapy as needed for tumor lysis or supportive care needs as directed by standard of care.
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- David McCall, MD(713) 792-6604
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson | Houston | Texas | 77030 | David McCall, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPHASE1 · Recruiting · Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas